Study to assess MEDI -578 in patients with Osteoarthritis (OA) of the knee

Study identifier:D2460C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase I, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess Safety,Tolerability, Pharmacokinetics and Efficacy of MEDI-578, an Anti-NGF Monoclonal Antibody, after Single Ascending Doses in Male and Non-fertile Female Patients with Painful Osteoarthritis of the Knee

Medical condition

Osteoarthritis, Pain

Phase

Phase 1

Healthy volunteers

No

Study drug

MEDI-578, Placebo for MEDI-578

Sex

All

Actual Enrollment

108

Study type

Interventional

Age

40 Years - 80 Years

Date

Study Start Date: 01 Feb 2010
Primary Completion Date: 01 Sept 2010
Study Completion Date: 01 Sept 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

MedImmune

Inclusion and exclusion criteria